BioCardia, Inc. Lease, Cost
BioCardia, Inc. (BCDA) reported Lease, Cost of $578.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-03-24
- BioCardia, Inc. lease, cost for the quarter ending 2019-12-31 was $213.00K.
- BioCardia, Inc. lease, cost for the quarter ending 2019-09-30 was $213.00K.
- BioCardia, Inc. lease, cost for the quarter ending 2019-06-30 was $213.00K.
- BioCardia, Inc. lease, cost for the quarter ending 2019-03-31 was $225.00K.
- BioCardia, Inc. lease, cost for fiscal 2025 was $578.00K, a 0.87% increase from fiscal 2024.
- BioCardia, Inc. lease, cost for fiscal 2024 was $573.00K, a 3.99% increase from fiscal 2023.
- BioCardia, Inc. lease, cost for fiscal 2023 was $551.00K, a 1.29% increase from fiscal 2022.
- BioCardia, Inc. lease, cost for fiscal 2022 was $544.00K, a 42.43% decline from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $578.00K 10-K · filed 2026-03-24 | |||
| 2024-12-31 | $573.00K 10-K · filed 2026-03-24 | |||
| 2023-12-31 | $551.00K 10-K · filed 2025-03-26 | |||
| 2022-12-31 | $544.00K 10-K · filed 2024-03-27 | |||
| 2021-12-31 | $945.00K 10-K · filed 2023-03-29 | |||
| 2020-12-31 | $996.00K 10-K · filed 2022-03-29 | |||
| 2019-12-31 | $213.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $426.00K derived: sum of 2 quarters · filed 2021-03-30 | $639.00K derived: sum of 3 quarters · filed 2021-03-30 | $865.00K 10-K · filed 2021-03-30 |
| 2019-09-30 | $213.00K 10-Q · filed 2019-11-19 | $426.00K derived: sum of 2 quarters · filed 2019-11-19 | $652.00K 10-Q · filed 2019-11-19 | |
| 2019-06-30 | $213.00K 10-Q · filed 2019-08-14 | $439.00K 10-Q · filed 2019-08-14 | ||
| 2019-03-31 | $225.00K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |